UCLA David Geffen School of MedicineLos Angeles, California, United States
Disclosure information not submitted.
Paper 21 - PHASE 1 RESULTS OF THE WEE1 INHIBITOR, AZENOSERTIB, IN COMBINATION WITH GEMCITABINE IN ADULT AND PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY OSTEOSARCOMA
Thursday, November 14, 20241:45 PM – 3:15 PM PST
Paper 69 - UPDATED EFFICACY, SAFETY, AND TREATMENT DISCONTINUATION OUTCOMES OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TRK FUSION SARCOMAS
Saturday, November 16, 20248:00 AM – 9:00 AM PST
Paper 102 - EFFICACY OF NIROGACESTAT IN PATIENTS WITH DESMOID TUMORS AND POOR PROGNOSTIC FACTORS: PATIENT-REPORTED OUTCOMES, PROGRESSION-FREE SURVIVAL, AND OBJECTIVE RESPONSE RATE IN THE PHASE 3 DEFI TRIAL
Saturday, November 16, 20243:30 PM – 4:30 PM PST
